Tag debug info: client: {"assets":{},"datasets":{},"live":{},"projects":{},"users":{},"observable":{"assets":{},"datasets":{},"live":{},"projects":{},"users":{}}} Now: 1770481373317 Cache Key: cqdTagPageBySlug:disease-modifying-therapy-dmt fetchCache[cqdTagPageBySlug:disease-modifying-therapy-dmt].expirationTime: falsey fetchCache[cqdTagPageBySlug:disease-modifying-therapy-dmt]. seconds remaining: falsey All fetchCache expiration times: -- Key: cqdNotFoundPage, seconds remaining: -968 -- Key: cqdTagPageBySlug:updates-in-general-surgery, seconds remaining: -2422 -- Key: cqdPostsByTag:cqd-migrated-tag-17577,1,10, seconds remaining: -2349 -- Key: cqdTagPageBySlug:microrna, seconds remaining: -968 -- Key: cqdPostsByTag:cqd-migrated-tag-3056,1,10, seconds remaining: -898 -- Key: cqdTagPageBySlug:organotypic-model, seconds remaining: 1099 -- Key: cqdPostsByTag:cqd-migrated-tag-19658,1,10, seconds remaining: 1397 -- Key: cqdTagPageBySlug:nursing-luminaries, seconds remaining: 5625 -- Key: cqdPostsByTag:cqd-migrated-tag-24988,1,10, seconds remaining: 5701 -- Key: cqdTagPageBySlug:retinal-vasculitis, seconds remaining: 6378 -- Key: cqdPostsByTag:cqd-migrated-tag-23079,1,10, seconds remaining: 6447 -- Key: cqdTagPageBySlug:hpv-screenings, seconds remaining: 7274 -- Key: cqdPostsByTag:cqd-migrated-tag-2958,1,10, seconds remaining: 7338 -- Key: cqdTagPageBySlug:myelin, seconds remaining: 7996 -- Key: cqdPostsByTag:cqd-migrated-tag-18309,1,10, seconds remaining: 8068 -- Key: cqdTagPageBySlug:jason-vanatta, seconds remaining: 8912 -- Key: cqdPostsByTag:cqd-migrated-tag-18438,1,10, seconds remaining: 8991 conditions: -- false, -- NA, -- NA, -- NA -- false Cache miss for key cqdTagPageBySlug:disease-modifying-therapy-dmt - retrieving from Sanity CCCache.dataFetchCount: 7484 Cache cleanup seconds remaining: 25625
Advertisement
Advertisement
Tag: disease-modifying therapy (DMT)
Rebound risk is shaped by patient characteristics and mechanism of action of current DMT
First-of-kind prediction model demonstrates high consistency across internal and external validation
Real-world study also finds no significant rise in ocrelizumab-related risk with advanced age
The disease is not a barrier to pregnancy, but risks from disease-modifying therapies must be managed
Advertisement
Cleveland Clinic is a non-profit academic medical center. Advertising on our site helps support our mission. We do not endorse non-Cleveland Clinic products or services. Policy
Risk of new MS activity is small in those older than 55 with stable disease who stop MS therapy
$1.1M award expands follow-up to six years with focus on clinical endpoints
Relapse rates were lower with oral or infusion therapy after initial injectable DMT
Observational studies comparing disease-modifying therapies can help guide clinical decisions
Unlikely to be severe, infections are associated with anti-CD20 therapies and fingolimod
Observational study suggests age may be a better guide than disease stability
Rendered: Sat Feb 07 2026 16:22:53 GMT+0000 (Coordinated Universal Time)
9500 Euclid Avenue, Cleveland, Ohio 44195 |
800.223.2273 | ©
2026 Cleveland Clinic. All Rights Reserved.
Search
